<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18185">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728610</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-2</org_study_id>
    <nct_id>NCT01728610</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms</brief_title>
  <official_title>Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms (IBS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyse the effect of a probiotic supplement on functional
      intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the intervention is to analyse the effect of a probiotic supplement in a
      dose-responsive set up on functional intestinal symptoms among subjects diagnosed with IBS
      according to Rome III criteria. Subjective assessment of bowel symptoms, quality of life,
      anxiety and depression and adequate relief will be assessed as with questionnaires as
      outcome measures. The intestinal microbiota will be analysed from faecal samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change in functional bowel symptoms</measure>
    <time_frame>0 weeks, 4 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validated questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>0 weeks, 4 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety and depression</measure>
    <time_frame>0 weeks, 4 weeks and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate relief</measure>
    <time_frame>Weekly over 3 month intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weekly question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in faecal microbiota</measure>
    <time_frame>0 weeks, 4 weeks, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Detection and quantification of microbes from faecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of investigational product</measure>
    <time_frame>Throughout the intervention phase</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Recording of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Active high</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic, high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic, low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic  (Active high)</intervention_name>
    <description>Higher dose of probiotic supplement</description>
    <arm_group_label>Active high</arm_group_label>
    <other_name>Lactobacillus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic (Active low)</intervention_name>
    <description>Lower dose of probiotic supplement</description>
    <arm_group_label>Active low</arm_group_label>
    <other_name>Lactobacillus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Maltodextrin as placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 to 65 fulfilling Rome III criteria for IBS will be recruited.
             Sufficient general health and orientation for participating in the study is required
             and will be evaluated by the MDs.

        Exclusion Criteria:

          -  Diagnosed or suspected organic gastrointestinal diseases or severely impaired general
             health.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lea Veijola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herttoniemi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Ouwehand, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sampo Lahtinen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anneli Tarpila, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lyra, PhD</last_name>
    <role>Study Director</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Lyra, PhD</last_name>
    <email>anna.lyra@dupont.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anneli Tarpila, PhD</last_name>
    <email>anneli.tarpila@dupont.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mehiläinen Töölö</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liisa Knaapi</last_name>
      <phone>+358 40 577 2965</phone>
      <email>liisa.knaapi@dupont.com</email>
    </contact>
    <contact_backup>
      <last_name>Päivi Kuusniemi</last_name>
      <email>paivi.kuusniemi@mehilainen.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Lea Veijola, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Turku</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Varantola, Research Nurse</last_name>
      <phone>02-4140207</phone>
    </contact>
    <contact_backup>
      <last_name>Anu Lillbacka, Research Nurse</last_name>
      <phone>02-4140207</phone>
    </contact_backup>
    <investigator>
      <last_name>Helena Kemppainen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiina Kojo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>October 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>probiotic</keyword>
  <keyword>pain</keyword>
  <keyword>bloating</keyword>
  <keyword>diarrhoea</keyword>
  <keyword>constipation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
